EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide

Natalia Roson-Calero iD, María A Gomis Font, Albert Ruiz-Soriano, Xavier Just-Baringo, María Eugenia Pachón-Ibáñez, J Pablo Salvador, M Pilar Marco iD, Ernest Giralt, Antonio Oliver iD, Clara Ballesté-Delpierre iD, Jordi Vila iD

Antimicrobial Agents and Chemotherapy · 13.02.2025 · 69 (2)

DOI: 10.1128/aac.01459-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 13.02.2025. Verfasst von Natalia Roson-Calero und 10 weiteren Autor:innen. Beteiligte Einrichtung: Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, Anti-Bacterial Agents, Peptides, Cyclic, Tetracyclines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación (MCIN), Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CIBERINFEC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pipeline for new drugs against multidrug-resistant Pseudomonas aeruginosa remains limited, highlighting the urgent need for innovative treatments. New strategies, such as membrane-targeting molecules acting as adjuvants, aim to enhance antibiotic effectiveness and combat resistance. RW01, a cyclic peptide with low antimicrobial activity, was selected as an adjuvant to enhance drug efficacy through membrane permeabilization. RW01’s activity was evaluated via antimicrobial susceptibility testing in combination with existing antibiotics on 10 P. aeruginosa strains and analog synthesis. Synergy was assessed using checkerboard assays, and one-step mutants were generated to identify altered pathways through whole-genome sequencing and variant analysis. Permeabilizing activity was studied using flow cytometry and real-time fluorescence measurement. In vivo toxicity was assessed in female C57BL/6J mice, and possible interaction with mouse serum was also evaluated. Susceptibility testing revealed specific synergy with tetracyclines, with up to a 16-fold reduction in minimum inhibitory concentrations. Sequencing revealed that resistance to the RW01-minocycline combination involved mutations in the pmrB gene, affecting outer membrane lipopolysaccharide composition. This was further confirmed by the identification of cross-resistance to colistin in these mutants. RW01 reduced the mutant prevention concentration of minocycline from 64 to 8 mg/L. RW01 was demonstrated to enhance membrane permeabilization and therefore minocycline uptake with statistical significance. Synthetic derivatives of RW01 showed a complete loss of activity, highlighting the importance of RW01’s D-proline(NH2) residue. No acute or cumulative in vivo toxicity was observed in mice. These findings suggest that RW01 could revitalize obsolete antimicrobials and potentially expand therapeutic options against multidrug-resistant P. aeruginosa .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas aeruginosaAnti-Bacterial AgentsPeptides, CyclicTetracyclinesAnimalsMicrobial Sensitivity TestsMiceFemaleDrug SynergismMice, Inbred C57BLDrug Resistance, Multiple, BacterialPseudomonas InfectionsMutation

Stichwörter der Autor:innen

Pseudomonas aeruginosaadjuvantsantimicrobial resistancecyclic peptidesmembrane disruption

Substanzen

Anti-Bacterial AgentsPeptides, CyclicTetracyclines

Autor:innen und Institutionen

  • Barcelona Institute for Global Health (ISGlobal), Barcelona, Spain.
  • Department of Basic Clinical Practice, School of Medicine, University of Barcelona, Barcelona, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Department of Microbiology, Hospital Universitario Son Espases, Health Research Institute of the Balearic Islands (IdISBa), Palma de Mallorca, Spain.
  • Laboratori de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, Barcelona, Spain.
  • Clinical Unit of Infectious Diseases, Microbiology and Parasitology, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain.

ORCID-Profile: Natalia Roson-Calero, M Pilar Marco, Antonio Oliver, Clara Ballesté-Delpierre, Jordi Vila

Förderung

  • Ministerio de Ciencia e Innovación (MCIN)
  • Government of Catalonia | Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)
  • Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CIBERINFEC)
  • MEC | Instituto de Salud Carlos III (ISCIII)

Zitieren

APA

Roson-Calero, N., Gomis Font, M. A., Ruiz-Soriano, A., Just-Baringo, X., Pachón-Ibáñez, M. E., Salvador, J. P., Marco, M. P., Giralt, E., Oliver, A., Ballesté-Delpierre, C., & Vila, J. (2025). In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide. Antimicrobial Agents and Chemotherapy, 69(2). https://doi.org/10.1128/aac.01459-24

Vancouver

Roson-Calero N, Gomis Font MA, Ruiz-Soriano A, Just-Baringo X, Pachón-Ibáñez ME, Salvador JP, et al. In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide. Antimicrobial Agents and Chemotherapy. 2025;69(2). doi:10.1128/aac.01459-24

BibTeX
@article{RosonCalero2025,
  author = {Roson-Calero, Natalia and Gomis Font, María A and Ruiz-Soriano, Albert and Just-Baringo, Xavier and Pachón-Ibáñez, María Eugenia and Salvador, J Pablo and Marco, M Pilar and Giralt, Ernest and Oliver, Antonio and Ballesté-Delpierre, Clara and Vila, Jordi},
  title = {In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {2},
  doi = {10.1128/aac.01459-24}
}
Kostenlos starten →